Literature DB >> 6681705

Effect of dazoxiben on arterial graft thrombosis in the baboon.

S R Hanson, L A Harker.   

Abstract

1 The thromboxane A2 synthetase inhibitor dazoxiben (UK 37248) was given orally to normal male baboons to determine its effect on platelet function in forming haemostatic plugs, and its capacity to prevent arteriovenous shunt and vascular graft thrombosis. 2 The standard template bleeding time was prolonged significantly at all doses ranging from 10-100 mg/kg (P less than 0.02 in all cases). 3 Doses ranging from 20-100 mg/kg daily did not normalize shortened platelet survival time or increased platelet destruction associated with chronic thrombogenic arteriovenous cannulae (P greater than 0.5). 4 A dose of 50 mg/kg did not reduce the rate or extent of acute platelet deposition on to Dacron vascular grafts (P greater than 0.5). 5 Despite significant inhibition of the platelets' capacity to form haemostatic plugs dazoxiben alone is ineffective in the prevention of prosthesis-related arterial thrombosis in the doses studied.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6681705      PMCID: PMC1427679          DOI: 10.1111/j.1365-2125.1983.tb02108.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone.

Authors:  A Kaegi; G F Pineo; A Shimizu; H Trivedi; J Hirsh; M Gent
Journal:  N Engl J Med       Date:  1974-02-07       Impact factor: 91.245

2.  Pharmacologic control of thromboembolic complications of cardiac-valve replacement.

Authors:  J M Sullivan; D E Harken; R Gorlin
Journal:  N Engl J Med       Date:  1971-06-24       Impact factor: 91.245

3.  The standardized normal Ivy bleeding time and its prolongation by aspirin.

Authors:  C H Mielke; M M Kaneshiro; I A Maher; J M Weiner; S I Rapaport
Journal:  Blood       Date:  1969-08       Impact factor: 22.113

4.  The estimation of blood platelet survival. II. The multiple hit model.

Authors:  E A Murphy; M E Francis
Journal:  Thromb Diath Haemorrh       Date:  1971

5.  In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis.

Authors:  S R Hanson; L A Harker; B D Ratner; A S Hoffman
Journal:  J Lab Clin Med       Date:  1980-02

6.  Experimental arterial thromboembolism in baboons. Mechanism, quantitation, and pharmacologic prevention.

Authors:  L A Harker; S R Hanson
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

7.  Thromboxane synthetase inhibition as antithrombotic strategy.

Authors:  J Vermylen; G Defreyn; L O Carreras; S J Machin; J Van Schaeren; M Verstraete
Journal:  Lancet       Date:  1981-05-16       Impact factor: 79.321

8.  Acetylation of prostaglandin synthase by aspirin.

Authors:  G J Roth; N Stanford; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

9.  Prevention of acquired transient defect in platelet plug formation by infused prostacyclin.

Authors:  T W Malpass; S R Hanson; B Savage; E A Hessel; L A Harker
Journal:  Blood       Date:  1981-04       Impact factor: 22.113

10.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

Authors:  M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.